Casadei-Gardini A et al. Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: An international study. ESMO 2022;Abstract SO-14.
Chau I et al. Nivolumab (NIVO) plus chemotherapy (chemo) or ipilimumab (IPI) vs chemo as first-line treatment for advanced esophageal squamous cell carcinoma (ESCC): Expanded efficacy and safety analyses from CheckMate 648. ESMO GI 2022;Abstract O-3.
Cohen SA et al. Real-world monitoring of circulating tumor DNA reliably predicts cancer recurrence in patients with resected stages I-III colorectal cancer. ESMO 2022;Abstract 319MO.
Dasari NA et al. FRESCO-2: A global phase III multiregional clinical trial (MRCT) evaluating the efficacy and safety of fruquintinib in patients with refractory metastatic colorectal cancer. ESMO 2022;Abstract LBA25.
Finn R et al. Primary results from the phase III LEAP-002 study: Lenvatinib plus pembrolizumab versus lenvatinib as first-line (1L) therapy for advanced hepatocellular carcinoma (aHCC). ESMO GI 2022;Abstract LBA34.
Goyal L et al. Updated results of the FOENIX-CCA2 trial: Efficacy and safety of futibatinib in intrahepatic cholangiocarcinoma (iCCA) harboring FGFR2 fusions/rearrangements. ASCO 2022;Abstract 4009.
Hammel P et al. Extended overall survival results from the POLO study of active maintenance olaparib in patients with metastatic pancreatic cancer and a germline BRCA mutation. ESMO 2022;Abstract 1298P.
He AR et al. Outcomes by primary tumour location in patients with advanced biliary tract cancer treated with durvalumab or placebo plus gemcitabine and cisplatin in the Phase 3 TOPAZ-1 study. ESMO GI 2022;Abstract O-1.
Kudo M et al. Final analysis of RATIONALE-301: Randomized, phase III study of tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma. ESMO 2022;Abstract LBA36.
Park W et al. Zolbetuximab plus gemcitabine and nab-paclitaxel (GN) in first-line treatment of claudin 18.2-positive metastatic pancreatic cancer (mPC): Phase 2, open-label, randomized study. ASCO 2022;Abstract TPS4186.
Pfeiffer P et al. Trifluridine/tipiracil (TAS-102) with or without bevacizumab in patients with pretreated metastatic esophagogastric adenocarcinoma (mEGA): A Danish randomized trial (LonGas). ESMO GI 2022;Abstract O-4.
Qin S et al. Health-related quality of life (HRQoL) impact of pembrolizumab (pembro) plus best supportive care (BSC) versus placebo (PBO) plus BSC as second-line (2L) therapy in patients (Pts) in Asia with advanced hepatocellular carcinoma (HCC): Phase 3 KEYNOTE-394 study. ASCO 2022;Abstract 4088.
Strickler J et al. Additional analyses of MOUNTAINEER: A phase II study of tucatinib and trastuzumab for HER2-Positive mCRC. ESMO 2022;Abstract LBA27.
Strickler J et al. MOUNTAINEER: Open-label, phase 2 study of tucatinib in combination with trastuzumab for HER2-positive metastatic colorectal cancer (SGNTUC-017). ESMO GI 2022;Abstract LBA-2.
Vogel A et al. Outcomes by baseline liver function in patients with unresectable hepatocellular carcinoma treated with tremelimumab and durvalumab in the phase 3 HIMALAYA study. ESMO GI;Abstract O-5.
Wyrwicz L et al. Reinforcing clinical outcomes with patient-reported QoL outcomes in patients with mCRC receiving FTD/TPI: Pooled analysis of PRECONNECT and TALLISUR studies. ESMO GI 2022;Abstract SO-18.
Yoon H et al. RATIONALE-306: Randomized, global, phase 3 study of tislelizumab plus chemotherapy versus chemotherapy as first-line treatment for locally advanced unresectable or metastatic esophageal squamous cell carcinoma (ESCC). ESMO GI 2022;Abstract LBA-1.
Yoshino T et al. Panitumumab (PAN) plus mFOLFOX6 versus bevacizumab (BEV) plus mFOLFOX6 as first-line treatment in patients with RAS wild-type (WT) metastatic colorectal cancer (mCRC): Results from the phase 3 PARADIGM trial. ASCO 2022;Abstract LBA1.